AstraZeneca today announced the completion of the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc, for the global rights to MEDI2070.
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease and ready for Phase II for ulcerative colitis, diseases that sit outside AstraZeneca’s three main therapy areas.
{iframe}https://www.astrazeneca.com/media-centre/press-releases/2016/MedImmune-completes-out-licensing-agreement-with-Allergan-for-MEDI2070-17112016.html{/iframe}